Kristen Karohl
Medical · Seven Hills, OHNPI 1942748926
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,465 and has fallen 50.1% since, to $1,230 in 2025. Among medical clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Johnson & Johnson$685
- Lundbeck LLC$642
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$633
- Alkermes, Inc.$572
- plus $2K from 11 others
What the payments were for
- Food & beverage$6,27098%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 56 | $1,172 |
| AbbVie | 53 | $1,059 |
| Johnson & Johnson | 26 | $685 |
| Lundbeck LLC | 38 | $642 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $633 |
| Alkermes, Inc. | 20 | $572 |
| Indivior Inc. | 28 | $388 |
| Neurocrine Biosciences, Inc. | 14 | $255 |
| Teva Pharmaceuticals USA, Inc. | 13 | $238 |
| Axsome Therapeutics, Inc. | 9 | $201 |
| Collegium Pharmaceutical, Inc. | 4 | $160 |
| Ironshore Pharmaceuticals Inc. | 6 | $113 |
| Supernus Pharmaceuticals, Inc. | 2 | $108 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Corium, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$501
- ABILIFY ASIMTUFII$246
- ABILIFY MAINTENA$246
- ARISTADA INITIO$125
- VRAYLAR$125
- CAPLYTA$125
- SPRAVATO$124
- REXULTI$123
- JORNAY PM$121
- INVEGA SUSTENNA$102
How this compares
$6,382 in reported general payments places this provider in the 90th percentile of 547 medical providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 44 | $60,712 |
| Abilify MaintenaAripiprazole | 11 | $32,149 |
| Paliperidone ErPaliperidone | 34 | $7,249 |
| Clozapine | 28 | $3,643 |
| Aripiprazole | 80 | $2,635 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $2,035 |
| Bupropion XlBupropion Hcl | 24 | $1,886 |
| Atomoxetine Hcl | 25 | $1,796 |
| Fluoxetine Hcl | 61 | $1,453 |
| Lurasidone Hcl | 11 | $1,390 |
| Quetiapine Fumarate | 94 | $1,202 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $990 |
| Ziprasidone Hcl | 21 | $984 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $884 |
| Prazosin Hcl | 15 | $749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,059 | $60,71244 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,172 | $32,14911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 547 medical providers in Ohio.
Other medical in Seven Hills
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Abbey BlairCleveland$24K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
- Kristen FairchildToledo$19K
- Kaitlin SchuppGahanna$17K
- Melanie HunglerCincinnati$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.